Trajan Wealth LLC Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

Trajan Wealth LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 80,202 shares of the medical research company's stock after purchasing an additional 3,179 shares during the quarter. Trajan Wealth LLC's holdings in IQVIA were worth $15,760,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC raised its position in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after purchasing an additional 77,981 shares during the period. Invesco Ltd. lifted its stake in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.2 %

IQV stock traded down $0.29 during midday trading on Friday, hitting $150.40. The stock had a trading volume of 703,678 shares, compared to its average volume of 1,416,746. The business has a 50-day moving average of $172.46 and a two-hundred day moving average of $194.57. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $26.52 billion, a price-to-earnings ratio of 20.04, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on IQV. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Mizuho decreased their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Barclays reaffirmed an "equal weight" rating and issued a $170.00 target price (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Finally, Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.